NICE Issues Recommendations for Bayer Cancer Drug

The National Institute for Health and Care Excellence issued recommendations for Bayer’s regorafenib as an option for metastatic or unresectable gastrointestinal stromal tumors in adults who have either seen progression on or are intolerant to prior treatment with imatinib and sunitinib.

Healthcare professionals should factor in any sensory, physical or learning disabilities and make necessary adjustments, according to the institute.

The drug meets NICE’s standards to be considered a life-extending end-of-life treatment, and can be recommended for use in the National Health Service.